Stemness was recently depicted as a dynamic condition in normal and tumor cells. We found that the embryonic protein Cripto-1 (CR1) was expressed by normal stem cells at the bottom of colonic crypts and by cancer stem cells (CSCs) in colorectal tumor tissues. CR1-positive populations isolated from patient-derived tumor spheroids exhibited increased clonogenic capacity and expression of stem-cell-related genes. CR1 expression in tumor spheroids was variable over time, being subject to a complex regulation of the intracellular, surface and secreted protein, which was related to changes of the clonogenic capacity at the population level. CR1 silencing induced CSC growth arrest in vitro with a concomitant decrease of Src/Akt signaling, while in vivo it inhibited the growth of CSC-derived tumor xenografts and reduced CSC numbers. Importantly, CR1 silencing in established xenografts through an inducible expression system decreased CSC growth in both primary and metastatic tumors, indicating an essential role of CR1 in the regulation the CSC compartment. These results point to CR1 as a novel and dynamically regulated effector of stem cell functions in colorectal cancer.
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Stemness was recently depicted as a dynamic condition in normal and tumor cells. We found that the embryonic protein Cripto-1 (CR1) was expressed by normal stem cells at the bottom of colonic crypts and by cancer stem cells (CSCs) in colorectal tumor tissues. CR1-positive populations isolated from patient-derived tumor spheroids exhibited increased clonogenic capacity and expression of stem-cell-related genes. CR1 expression in tumor spheroids was variable over time, being subject to a complex regulation of the intracellular, surface and secreted protein, which was related to changes of the clonogenic capacity at the population level. CR1 silencing induced CSC growth arrest in vitro with a concomitant decrease of Src/Akt signaling, while in vivo it inhibited the growth of CSC-derived tumor xenografts and reduced CSC numbers. Importantly, CR1 silencing in established xenografts through an inducible expression system decreased CSC growth in both primary and metastatic tumors, indicating an essential role of CR1 in the regulation the CSC compartment. These results point to CR1 as a novel and dynamically regulated effector of stem cell functions in colorectal cancer. Increasing evidence suggests that stemness is not a static condition, neither in normal cells nor in cancer. 1, 2 Spontaneous interconversion between states of higher and lower stemness has been observed both in embryonic stem cells (ESCs) and in adult tissues. [3] [4] [5] [6] In cancer, the transition between stem cells and non-stem cells is critical to the maintenance of a phenotypic equilibrium in which cell populations rapidly regulate relative hierarchic proportions in response to external stimuli. 7 Stem cell dynamics have been particularly studied in the intestinal epithelium, where recent studies provided impressive insight on the behavior of normal stem cells. 8 By contrast, the comprehension of stem cells dynamics in colorectal cancer (CRC) is at its beginning, although cancer stem cells (CSC) plasticity has been observed as the result of therapeutic and microenvironmental factors and proposed to influence patient outcome. 9 In particular, the extracellular cues that regulate stem cell metastability in CRC remain largely unknown. Cripto-1 (CR1), also known as teratocarcinoma-derived growth factor-1 (TDGF-1), is an extracellular glycosylphosphatidylinositol (GPI)-anchored protein expressed in mouse and human ESCs, where it regulates stem cell differentiation. 10 CR1 is usually low or absent in adult tissues but is reactivated in pathological conditions. Indeed, CR1 expression is rapidly induced in skeletal muscle upon acute injury and it is required in the muscle stem cell (satellite cell) compartment to promote efficient tissue regeneration.
11 CR1 is also overexpressed in several types of human tumors 12 where it has a functional role in malignant transformation. 13 Intriguingly, CR1 was found to be expressed in human ESCs with the highest self-renewal potential and was identified as a potential surface marker for an undifferentiated subpopulation in human embryonic carcinoma cells. 14, 15 We found that CR1 is expressed by cells at the bottom of colonic crypts in normal human and mouse colon and by CSCs in human tumor tissues. In multicellular spheroid cultures of patient-derived colon cancer cells, CR1 expression was subject to a complex regulation at the intracellular, surface and secreted levels, which reflected the amount of selfrenewing cells. Furthermore, CR1 silencing decreased CSC numbers and tumor growth, pointing to a functional role of this protein in regulating the size of the CSC compartment.
Results
CR1 is expressed in stem cells compartments in normal colon and CRC. Colon cancer spheroids derived from primary human tumors have been previously demonstrated by our laboratory and others to be enriched in CSCs. [16] [17] [18] Three CRC specimens (detailed in Supplementary Table S1) were obtained at the time of surgical resection and established as multicellular spheroid cultures in serum-free media. Spheroids were mainly composed by CD133 + cells, indicating that they are prevalently composed by stem cells/transit-amplifying progenitors 19 but also contained several cells positive for cytokeratin-20 (CK20) representing a more differentiated fraction. Culture in serum-containing medium led to cell adherence, loss of the AC133 epitope and widespread CK20 expression ( Figure 1a and Supplementary Figure 1a) . We analyzed the expression and localization of colon-specific and common stem cell markers in colon spheroids and spheroid-derived adherent cells (SDAC) and found that, among others, CR1 was strongly downregulated in SDAC both at the intracellular and at the surface level (Figure 1b, Supplementary Figure 1b and Figure 1c , respectively). Flow cytometry analysis of CR1 expression showed variable levels of CR1 + cells in spheroid lines derived from different patients (between 8 and 33%, Figure 1d ). To investigate whether CR1 was associated with known stem cell markers in CRC spheroids, we analyzed its expression relative to Lgr5, Nanog and Ephrin B2 receptor (EphB2) and found that CR1 + cells represented a fraction of the EphB2 high or Nanog + population and partly overlapped with Lgr5 + cells (Figure 1e ). To further investigate CR1 expression and localization in the colon, we analyzed tissue sections of normal and neoplastic colon and found that CR1 + cells localized at the bottom of colonic crypts in normal mouse (both neonatal and adult, Figures 1f and g ) and human colon (Figure 1h ), whereas CR1 expression was deregulated in cancer, being widely present in neoplastic tissues of either mouse and human origin (Figures 1g and h ). The expression of CR1 in the colon stem cell compartment was confirmed by double staining for CR1 and Lgr5 or EphB2. Double-positive CR1/Lgr5 + or CR1/EphB2 high cells were observed both in normal colon (in rare cells residing at the bottom of the crypts) and in colon adenocarcinoma, with a concentrated presence at the invasive front of the tumor suggesting a potential role for CR1 + cells in modulating epithelial-mesenchymal transition and metastatic spread (Figure 1h ). The link between CR1 expression and colorectal CSCs was further supported by the observation that the expression of CR1 in CRC patients correlates with high expression of EphB2 or Lgr5 (Supplementary Figure 1c) . These results confirm previous reports that CR1 is expressed in the neoplastic colon 12 and show for the first time its presence in the stem cell compartments of normal colon and CRC.
CR1 positivity in tumor spheroids oscillates in correspondence to increased stemness states. To gain further insights on the role of CR1 in CSCs, we monitored its expression in colon tumor spheroids over time and we found a marked oscillation of CR1 surface levels, which fluctuated between~1 and 60% with a rough sinusoidal distribution (Figure 2a and Supplementary Figure 2a) . Peaks of CR1 positivity corresponded to an increased clonogenic capacity of the whole spheroid population (Supplementary Figure  2a) , suggesting a potential correlation between CR1 expression and stemness potential. In contrast, the expression of other CSC markers such as CD133 and Lgr5 remained constant over time (Supplementary Figure 2a) . The fluctuation of CR1 expression was not influenced by oxygen conditions (Supplementary Figure 2b) and was not determined at the transcriptional level, as CR1 RNA did not show significant differences when monitored in parallel to surface expression (Supplementary Figure 2c) . To explore the correlation between CR1 expression and stem cell properties, we separated spheroid cells positive and negative for CR1 expression at different time points and evaluated their ability to generate colonies in soft agar, assuming that cells with increased stemness capacity were those able to form larger colonies. We found a significant correlation between the generation of large colonies and the presence of CR1-positive cells (Figure 2b) , indicating a causal correlation between CR1 positivity and clonogenic capacity. Then, we separated CR1-positive and CR1-negative spheroid populations to monitor their behavior in liquid culture and to assess the presence of stem cellrelated features. Remarkably, purified CR1 + and CR1
− populations showed rapid modifications of surface CR1 levels, with CR1 + cells undergoing an abrupt loss of CR1 expression (from 90 to 10% after 7 days) whereas CR1 − cells acquired relatively high levels of CR1 expression (approximately from 0 to 40%; Figure 2c ). After sorting, CR1 expression shortly recovered its tendency to oscillate, but with different phases in the two sorted populations. Finally, we assessed whether CR1-positive cells displayed enhanced stem cell features by analyzing Nanog and Lgr5 mRNA levels and β-catenin localization in sorted cells. We found that CR1-positive cells had increased levels of Nanog and Lgr5 and a significantly higher nuclear positivity of β-catenin (Figures 2d and e) , suggesting an enrichment of CSCs. Altogether, these observations suggest that CR1 levels are regulated in CSCs/progenitors both in basal conditions (in undisturbed spheroid cultures) and upon perturbation (after sorting), possibly reflecting fluctuations of the stem/progenitor cell compartment in response to intrinsic and extrinsic cues.
Synchronized clonal fluctuations are responsible for CR1 oscillation in CSC-enriched cultures. To examine more in depth the dynamics of CR1 oscillation, we first monitored surface CR1 expression in three patient-derived spheroid lines, which all showed a rough sinusoidal trend although with different phases (Figure 3a) . Then, we ought to understand whether the levels of CR1 were regulated at the clonal level and whether different clones in spheroid cultures displayed independent levels of CR1. To do this, we transduced cells derived from one spheroid line with vectors encoding for six different fluorescent proteins to allow multicolor clonal cell marking. 20 Transduced cells were sorted and cloned, and single clones were subsequently assessed for the respective expression of fluorescent proteins, which displayed a remarkable stability over time as previously reported (Figure 3b ). Colored clonal cell populations were then pooled (two pools of three clones each) and CR1 expression was monitored over time for each clone. We found that clones belonging to the same pooled population showed a similar trend of CR1 surface levels (Figure 3c ), suggesting that the dynamics of CR1 expression are dictated by population forces rather than by independent clonal features. further insights into the process of CR1 fluctuation, we analyzed the presence of CR1 in different cellular compartments (cytoplasm, total cell membranes and plasmamembrane) and in the extracellular milieu, where it can be released to exert a paracrine activity on surrounding cells. 21, 22 To do this, we collected lysates of subcellular fractions from cultured spheroid cells once a week for 5 weeks. We verified the purity of cellular fractions by immunoblotting against compartimentalized proteins and detected the presence of CR1 in the cytosolic and total membrane fractions, as expected (Supplementary Figure 3) . In parallel, we monitored CR1 surface expression by flow cytometry and we assessed the levels of CR1 released in the extracellular medium by ELISA. Interestingly, we found that CR1 levels were subject to fluctuations not only on the cell surface but also in the cytoplasmic and total membrane compartments and in the extracellular medium (Figure 4 ). Higher levels of the unmodified form of CR1 in the cytoplasm corresponded to increased CR1 release and to a lower surface expression, while the modified (i.e., glycosylated and fucosylated 23 ) protein was increased in correspondence to low extracellular levels and high-surface expression. These observations indicate that CR1 protein is subject to multiple levels of regulation, not only by posttranslational modifications but also by intracellular compartimentalization and extracellular release.
CR1 and the downstream activation of the Glypican-SrcAkt pathway are essential for CSC growth. To investigate the functional role of CR1 in colorectal stem-progenitor cells, we treated spheroid cell lines with small interfering RNAs (siRNAs) to induce a transient decrease in CR1 expression. CR1 siRNA were effective in reducing CR1 RNA levels and resulted in a significant inhibition of colony size in semisolid culture (Figures 5a and b) . Then, we carried out stable CR1 silencing by using lentiviral vectors containing two different shRNA sequences (detailed in Supplementary Table 2 ). The two sequences were both able to induce a strong reduction in CR1 RNA levels, although at a different extent, in spheroids (Pt1) as well as in NTERA2 teratocarcinoma cells (Figure 5c ). Functionally, the two shRNAs induced, respectively, a complete abrogation or a strong reduction of colony formation in soft agar (Figure 5d ) and an equivalent growth inhibitory effect in liquid culture (Figure 5e ). Cell cycle analysis of CSC stably expressing CR1 shRNA4890 4 days after transduction showed an accumulation of cells in the G2/M phase of the cycle (from 11.6 to 26.2%) and a corresponding decrease of cells in G1 (from 66.5 to 45.4%; Figure 5f ). The number of hypodiploid cells did not change in CR1-silenced CSC, but we observed a small increase in the percentage of debris/ sub-hypodiploid cells generally indicative of cell death (Debri/ Apo from 2.2 to 6.6%; Figure 5f , right panels). CR1 has been demonstrated to signal through a Nodal-dependent and a Nodal-independent pathway, 24 the latter being activated by CR1 binding to Glypican-1 and downstream activation of c-Src and Akt signaling. To gain insights into the pathway active downstream of CR1 in colon CSCs, we assessed the expression of ALK4, Nodal, Glypican-1 and the co-receptor GRP78 in spheroid cells and found that such factors were all expressed at the RNA and protein level (Supplementary Figure 4) . Then, we evaluated the effect of CR1 silencing on the levels of CR1 signaling partners and of selected proteins involved in cell cycle and apoptosis regulation. Levels of CR1, phospho-Smad2, Glypican-1, phospho-Src and phospho-Akt sensibly decreased in silenced cells, whereas levels of Alk4 slightly increased. In CR1-silenced cells we also observed an increase in polo-like kinase 1 and cyclin D1, confirming the accumulation of cells in the G2/M phase of the cell cycle. In addition, we observed a small amount of cleaved PARP in silenced cells, indicating the occurrence of low levels of cell death ( Figure 5g ). These results suggest that CR1 is linked to the activation of the Glypican-Src-Akt pathway in colorectal CSCs/progenitors, although we cannot rule out that Nodaldependent signaling may have a role in other cellular systems and in patient tumors.
CR1 downregulation inhibits tumor progression and decreases CSC content in vivo.
To investigate the effects of CR1 silencing in vivo, we employed a Tet-inducible lentiviral silencing system that allowed us to achieve CR1 silencing at different stages of tumor formation and progression. The sh4890 CR1 silencing sequence was cloned into the TRIPZ Tet-inducible lentiviral vector, which achieved 75% reduction of CR1 RNA levels as compared with controls ( Figure 6a ). CR1 downregulation inhibited spheroid proliferation and strongly reduced colony formation in semisolid culture (Figures 6b and c). Cells were then injected subcutaneously in three groups of immunecompromised (NOD/SCID ɣ-chain deficient, NSG) mice in order to compare the growth of tumors generated from control cells (transduced with the silencing construct but not induced with doxycycline, thereafter referred to as non-induced), from cells in which CR1 expression was silenced either at the time of injection (shCR1 induced from day 0) or at the appearance of palpable tumors (shCR1 induced from day 21). Tumor xenografts were then monitored for 1 month. Tumors generated by cells with CR1 silenced from day 0 grew at a significantly reduced growth rate (Figure 6d ). Notably, also tumors in which CR1 expression was silenced at day 21 also had a significantly, although less pronounced, reduced growth rate compared 
Pt1
Pt2 Pt3 Figure 6d ). Importantly, an ex vivo analysis of the clonogenic capacity of cells extracted from the xenografts showed that CR1 silencing strongly reduced the number of colony-forming cells (Figure 6e ). Moreover, when we analyzed the effect of CR1 silencing with serial transplantation/ limiting dilution assays, we found that CR1-silenced cells gave rise to secondary tumors with increased latency, reduced volume and decreased frequency as compared with controls, indicating that CR1 downregulation affects the number of tumor-initiating cells (TICs) in vivo (Figure 6f ). Stem cell quantification of results shown in Figure 6f with the Extreme Limiting Dilution Analysis (ELDA) method 25 indicated an estimated proportion of 1/18 TICs in the Vector group and 1/69 TICs in the CR1-silenced group (*Po0.05). Altogether, these results suggest that CR1 has a role in both tumor initiation and progression through regulation of the CSC compartment.
CR1 is essential for CSC growth at metastatic sites. A subpopulation of colon CSC, which has been recently shown to be characterized by CD44v6 expression, possesses increased migratory and metastatic properties. 26 Double staining of CSC spheroids for CR1 and CD44v6 showed that the majority of CR1 + cells expressed also CD44v6 (11.4% CR1 + CD44v6 + versus 3.9% CR1 + CD44v6 − ; Figure 7a ). In line with a potential role of CR1 in the regulation of CSC migratory abilities, spheroid cells with silenced CR1 expression showed a significantly reduced migration in transwell assays (Figure 7b ). To verify whether CR1 silencing would also affect metastatic growth in vivo, colon spheroids were double transduced with the inducible CR1-silencing vector and with a luciferase reporter vector to allow for tumor bioimaging. Transduced spheroid cells were then treated with doxycycline to induce CR1 silencing and injected in the tail vein of NSG mice, which received doxycycline in the drinking water to maintain CR1 silencing throughout the experiment. Four months after injection, noninduced control cells gave rise to lung metastases in all injected mice, whereas CR1-silenced cells produced very few metastases (Figure 7c ), indicating an essential role of CR1 for CSC growth at metastatic sites. To provide additional support to a role of CR1 in metastatic CSC growth, we injected double-transduced spheroid cells in the spleen of NSG mice and we waited~1 month to allow tumor formation (Figure 7d ). Tumor-bearing mice were then splenectomized and divided into two groups, which were, respectively, left non-induced or administered doxycycline to activate CR1 silencing (Figure 7d ). Mice were regularly monitored through bioimaging for the appearance and growth of liver metastasis. Control (non-induced) mice had a significantly increased rate of metastasis growth as compared with mice in which CR1 was silenced (Figure 7e ), further supporting a role for CR1 in the growth of metastatic CSCs.
Discussion
In line with the emerging concept of stem cell plasticity in normal and neoplastic tissues, we identified the ESC marker CR1 as a protein dynamically expressed on CRC cells. The dynamic behavior of CR1 was apparent in multicellular spheroids of patient-derived cells (composed by a large majority of CD133 + stem/progenitor cells) both in basal culture conditions and upon separation of CR1-positive and -negative cell populations, which rapidly changed CR1 surface expression. CR1 expressed on the membrane of colorectal stem/progenitor cells was not simply unstable but followed a roughly sinusoidal trend, reminescent of fluctuations in stemness regulators that have been shown to occur in ESCs and to have a key role in the maintenance of pluripotency. 3, [27] [28] [29] [30] The parallel between the fluctuations of CR1 and that of stemness factors is reinforced by the observation that cells with the highest expression of CR1 have an increased clonogenic potential, indicating their enrichment in self-renewing elements. Notably, the fluctuation of cellular factors is generally attributed to oscillations of gene expression. By contrast, fluctuations of CR1 occurred upon small variations in transcript levels but in the presence of consistent changes in the subcellular and extracellular distribution of the protein. In this regard, we show for the first time that CR1 is released by CSCs/ progenitor cells, possibly representing a mechanism that contributes to a cross-talk between tumor cells. In line with this hypothesis, stemness has been recently described as a statistical property of cell populations (rather than a property of individual cells) that depends both from cell-intrinsic mechanisms and from cell-to-cell signals that act as system-level feedback mechanisms. 31, 32 Identifying the molecular cues of intercellular coordination will be essential to interfere with the adaptive responses of cancer cells to external challenges and ultimately to achieve long lasting therapeutic effects.
We showed that the cyclic fluctuation of surface CR1 reflects the synchronized expression pattern of different cell clones present in the same culture. This observation suggests the existence of feedback mechanisms that coordinate CR1 expression of clones coexisting in the same cell population. This phenomenon would result in the waves of high CR1 expression in the whole cancer cell population, corresponding to the waves of high clonogenic potential. Furthermore, this observation suggests the existence of a coordinated behavior in the cancer cell population, similar to the mechanisms of quorum sensing that have been previously postulated on the basis of mathematical models 33 and experimentally observed in human cell lines. 
In normal human and mouse colon, CR1 was expressed by cells located at the bottom of the crypts possibly representing a marker of normal colorectal stem cells. However, the role of CR1 in normal colon is still unknown, as CR1 knockout embryos die at an early stage due to gross defects in embryonic symmetry. 35 The expression of CR1 was deregulated in CRC, as previously reported, 36 being present on cancer cells particularly at the invasive front of the tumor. Despite its diffuse expression on cancer cells, our results show that the highest levels of CR1 expression are present in Lgr5 + cells and EphB2 high cells, indicating that CR1 may have a specific role in CSC regulation. The supposed role of CR1 in CSCs seems corroborated by the observation that CR1 silencing profoundly affects signaling pathways essential for CSC growth. Specifically, CR1 silencing results in a strong decrease of pAkt, which has been recently indicated as a key factor in colorectal CSC survival specifically expressed by the tumorigenic/ metastatic fraction. 26 Accordingly, our results show that a reduction of CR1 expression in tumor xenografts inhibits tumor growth and induces a decrease of CSC numbers. Moreover, we observed that CR1 silencing inhibited the growth of metastatic CSCs in mouse lungs and liver, suggesting that CR1 may be important for CSC expansion at metastatic sites. These findings may explain the correlation between elevated CR1 levels and the presence of metachronous metastases found in colon cancer patients, 37 also corroborating the hypothesis that the state of the CSC compartment may be related to patient prognosis. 38 Altogether, these results indicate CR1 as a new functional player of CRC stem/progenitor cell regulation and highlight the dynamic behavior of these cells, which should be taken into account in order to devise effective anticancer strategies.
Materials and Methods
Cells and tissues. Colon cancer specimens were obtained from patients undergoing surgical resection upon informed consent and approval by the Istituto Superiore di Sanità (ISS) Ethical Committee. Spheroid cultures were established in serum-free medium containing 20 ng/ml EGF and 10 ng/ml bFGF (PeproTech, Rocky Hill, NJ, USA) and subsequently kept on ultra-low attachment dishes (Nunc, Sigma-Aldrich, St. Louis, MO, USA) in a 5% CO 2 humidified incubator at 37°C as described. 39 Spheroids were routinely tested for their ability to produce colon adenocarcinomas histologically identical to the human tumors of origin when injected into NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (The Jackson Laboratory, Ann Arbor, MI, USA). SDAC were obtained by culturing spheroid cells in 10% serum-containing DMEM (Gibco-Invitrogen, Carlsbad, CA, USA) for 10 days. Mouse colon samples were obtained either from healthy neonatal or adult animals or mice with sporadic high-grade adenoma (Apcflox; LSL-KrasG12D). Human colon samples were obtained from formalin-fixed paraffin-embedded (FFPE) surgical specimens of neoplastic and peritumoral (referred to as normal) tissue.
Antibodies and reagents. Polyclonal antibodies against CR1 used for immunofluorescence and flow cytometry analyses were produced by immunizing rabbits with purified recombinant soluble CR1 produced in 293 cells. 40 Monoclonal antibodies against Lgr5 (both conjugated and unconjugated) and CD133 (AC133 epitope) were obtained from Miltenyi Biotec (Bergisch Gladbach, Germany). Antibodies against CD44v6, Nanog, Musashi, Sox2 and EphB2 (the latter both Alexa Fluor 488-conjugated and unconjugated) were obtained from R&D System Inc. (Minneapolis, MN, USA). Anti-CK20 was from Dako (Carpinteria, CA, USA). Alexa Fluor-conjugated secondary antibodies were obtained from Invitrogen Molecular Probes. Anti-Alk4, cyclin D1, Glypican-1 and TIM23 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-β-actin, GAPDH and PARP were from Sigma-Aldrich. Total Src, p-Src, p-AKT, total AKT, p-smad2, smad2, CD44, polo-like kinase 1, Bmi1 and β-catenin were from Cell Signaling Technology (Danvers, MA, USA). Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish peroxidase were from GE Healthcare (Uppsala, Sweden).
Cell proliferation and self renewal assays. Cell proliferation was analyzed with the Cell Titer GLO assay (Promega, Madison, WI, USA) as described 39 with a DTX880 plate reader (Beckman Coulter, Brea, CA, USA). For clonogenic assays, dissociated spheroids were plated in triplicate at 500 cells/well suspended in 0.3% agarose over a layer of 0.4% agarose. Plates were incubated in a 5% CO 2 humidified incubator at 37°C and colony counts were performed from Thermo Scientific/Life Technologies (Carlsbad, CA, USA). For stable CR1 silencing, the lentiviral pLKO.1 silencing vectors containing either a non-targeting sequence, the sh4889 or sh4890 sequences that target the 3′-UTR and the coding sequence of CR1, respectively, were purchased from Sigma-Aldrich. The sh4890 sequence was subsequently cloned in the TRIPZ lentiviral inducible vector (Thermo Scientific/ Life Technologies). The lentiviral reporter vector TWEEN-Luc-GFP was constructed by using pRRL-CMV-PGK-GFP-WPRE (pTWEEN) as a backbone for subcloning a firefly luciferase NheI/XbaI cDNA fragment extracted from pGL3 (Promega) into the XbaI site at the 3′ of the CMV promoter.
Clonal marking. Six different lentiviral vectors were used to transduce spheroid cells: LeGO-C2 (mCherry), LeGO-V2 (Venus), LeGO-Cer2 (Cerulean), TWEEN-GFP (green), TWEEN-RedFP (red) and pLOX-CFP (Cyan). Cells were separated on the basis of fluorescent protein expression and single clones were derived from each fluorescent cell culture by single-cell automated sorting on a 96-well plate. After 1 month, three single-cell-derived spheres for each color were expanded, tested for fluorescent protein expression and one clone of each color was used for subsequent experiments.
Whole-mount in situ hybridization. A DNA template was generated from mouse cDNAs encoding CR1 (entire open reading frame). Antisense RNA probes were synthesized from 1 μg of linearized cDNA and labeled with either digoxigenin-UTP (Roche Diagnostics Corporation, Indianapolis, IN, USA) using T3, T7 and SP6 RNA polymerases (Promega). The transcription reaction was carried out at 37°C for 2 h, followed by DNaseI treatment (Promega). After the quality of the labeled RNA was assessed by gel electrophoresis, transcripts were ethanol precipitated in 7.5 M LiCl and TE of pH 8.0 and stored overnight at − 80°C. Probes were resuspended in hybridization solution and stored at − 80°C. Mouse intestines were dissected, washed in PBS and fixed in 4% paraformaldehyde (PFA) in PBS at 4°C. In situ hybridization was performed on 5 μm paraffin-embedded sections. After rehydration in PBS containing 0.1% Tween20 (PBT), sections were treated with proteinase K (10 mg/ml) for 3-20 min, and then postfixed in 4% PFA plus 0.2% glutaraldehyde. Proteinase K was inactivated with 0.2% glycine in PBT. All samples were incubated in hybridization buffer containing 50% formamide for 2 h at 70°C and then hybridized at the same temperature with 0.5 μg/ml labeled RNA probe overnight. Posthybridization washes and RNase A treatment (100 μg/ml) were subsequently performed. Tissues were rinsed 3 × 5 minutes in maleic acid buffer (MAB; 0.1 M maleic acid of pH 7.5, 0.15 M NaCl, 0.1% Tween20 and 0.002 M levamisole) and then incubated in blocking buffer (MAB 10% sheep serum, and 2% blocking reagent, Roche Diagnostics Corporation), at room temperature for 3 h. Hybridized probes were incubated with preabsorbed anti-digoxigenin-AP antibody (Roche Diagnostics Corporation) diluted 1 : 4000 in blocking buffer (Roche Diagnostics Corporation) overnight at 4°C. Tissues were washed several times with MAB at room temperature, and then developed with BM purple (Roche Diagnostics Corporation) color substrate for 5-16 h. Reactions were then stopped with 3 × 5 minutes PBT washes, and samples postfixed in 4% PFA plus 0.2% glutaraldehyde.
Immunofluorescence. Colon cancer spheroids were cytospun at low speed on polylysine-coated glass slides, whereas SDAC were grown on matrigel-coated coverslips. Typically, cells were fixed in 2% PFA and permeabilized in 0.1% Triton X-100 (Bio-Rad Laboratories, Hercules, CA, USA) then incubated overnight at 4°C with primary antibodies (described in the Antibodies and Reagents section) dissolved in PBS containing 3% BSA, 0,1% Triton X-100. After two washes in PBS, cells were incubated with Alexa Fluor-conjugated secondary antibodies for 30 min at room temperature in the dark, stained for 15 min with DAPI (Invitrogen) diluited in PBS 3% BSA and subsequently mounted with Prolong-Gold antifade (Invitrogen).
Immunofluorescence staining of FFPE normal and neoplastic human colon tissue sections was performed as follows: sections were deparaffinized, washed in PBS and incubated with anti-CR1 antibody 40 (1 : 50 in PBS) overnight at 4°C. After washing in PBS, sections were incubated with a FITC-conjugated secondary antibody (1 : 200 in PBS) 1 h at 37°C and then treated with 4% PFA for 30 min at room temperature. After an additional washing in PBS, sections were permeabilized with a brief incubation in a microwave oven with Epitope Retrieval pH-6 (Novocastra-Leica Biosystems, Richmond, IL, USA) followed by 10 min incubation with cold 0.1% Triton X-100. After washing in PBS, sections were incubated overnight at 4°C with anti-EphB2 (1 : 100 in PBS/3% BSA/0.05 Tween20) or antiLgr5 (1 : 100 in PBS/3% BSA/0.05 Tween20) antibodies. After incubation with rhodamine-conjugated secondary antibodies, nuclei were stained with TOTO-3 (Invitrogen Molecular Probes) and sections were mounted with Prolong-Gold antifade. Slides were analyzed on a FV1000 confocal microscope (Olympus, Tokyo, Japan) equipped with 40 × and 60 × oil immersion objectives and the Olympus Fluoview software.
Flow cytometry and sorting. Spheroid-dissociated cells were labeled with primary antibodies (PE-conjugated anti-Lgr5, Alexa Fluor 488 conjugated anti-EphB2 or non-conjugated anti-CR1, described in the Antibodies and Reagents section) for 1 h on ice and, where necessary, with secondary antibodies for 30 min on ice, then sorted with a FACSAria (BD Biosciences, San Jose, CA, USA) or analyzed with a FACSCanto flow cytometer equipped with a DIVA software (BD Biosciences). 10 μg/ml 7-aminoactinomycin D (Sigma-Aldrich) was always added for dead cell exclusion. The cell cycle status of colon CSC was assessed by staining dissociated spheroids with 50 μg/ml propidium iodide dissolved in buffer 0.1% trisodium citrate, 9.65 mM NaCl, 0.1% NP40, 200 μg/ml RNAse for 1 h at room temperature. Analysis of debris/apoptotic cells was performed by gating the desired area of the plot on the basis of physical parameters and subsequent fluorescence analysis on a logarithmic scale.
Quantitative real-time PCR. Total RNA was extracted with TRIzol (Invitrogen) following manufacturer's instructions. 50 ng of RNA were reverse transcribed with M-MLV reverse transcriptase (Invitrogen) and 200 ng of cDNA were used as template in the PCR reactions. Specific primers (specified in Supplementary Table 3) were used for Nanog, CR1, Nodal, Glypican, ALK4 and GRP78, while a TaqMan assay (Applied Biosystems/Life Technologies, Carlsbad, CA, USA; Cat. 4351372) was used for Lgr5 amplification. Normalization was performed using β-actin as reference (TaqMan assay, Applied Biosystems/Life Technologies, Cat. 4310881E) for Nanog, CR1 and Lgr5 and GAPDH for Nodal, Glypican, ALK4 and GRP78. Values are expressed in terms of 2-ΔΔCT where ΔΔCT = ΔCTsample − ΔCTcalibrator. ΔCT is the difference in threshold cycles between the specific RNA and β-actin amplicons, and CT is a parameter given by StepOne Plus Real-Time PCR software by negative correlation with an internal reference dye (ROX).
Western blotting. Cell lysates were obtained from approximately 2.5 × 10 5 spheroid cells by incubation of cell pellets in 1% NP40 lysis buffer (20 mM Tris HCl pH 7.2, 200 mM NaCl, 1% NP40) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktails I and II (all from Sigma-Aldrich). Lysate concentrations were determined by the Bradford assay (Bio-Rad Laboratories) and equal amounts of proteins were loaded on a 12% precast gel (Invitrogen) and transferred to nitrocellulose membranes. Blots were blocked with TBST 5% nonfat dry milk and incubated overnight at 4°C with primary antibodies (described in the Antibodies and Reagents section), then incubated for 45 min with secondary HRP-conjugated ELISA assay. 96-well plates were coated with 4 μg/ml of mouse anti-human CR1 Ab (R&D Systems Inc., Cat. 842077) in PBS (137 mM NaCl; 2,7 mM KCl; 8,1 Na 2 HPO 4 ; 1.5 mM KH 2 PO 4 pH 7.5) overnight at 4°C and then washed three times with PBS-Tween20 0.05%. Aspecific binding sites were blocked with PBS-BSA 1% . After 1 month, the spleen was removed and mice were divided into two groups, one of which was left untreated (Noninduced) while the other received doxycycline in the drinking water to activate CR1 silencing (shCR1 after splenectomy). Mice were monitored for the growth of liver metastases (central panels), which were quantified by bioimaging (right graph). **Po0.01
Dynamic regulation of cancer stem cells by Criptograded ethanol washes. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol for 10 min. Antigen retrieval was performed by autoclaving slides in citrate buffer (pH 6.0). CR1 protein was stained with anti-mouse-CR1 mAb (B3F6, Biogen Idec, Weston, MA, USA) and the Vectastain ABC kit (Vector Laboratories Inc, Burlingame, CA, USA) following the manufacturer's instructions. Sections were counterstained with hematoxylin.
Motility assay. 1 × 10 4 control or CR1-interfered CSCs were suspended in 200 μl of non-supplemented stem cell medium and plated into the upper wells of matrigel-coated modified Boyden Chambers containing porous 8 mm diameter polycarbonate membranes (Costar Scientific Corporation, Cambridge, MA, USA). Lower wells contained 500 μl of stem cell medium supplemented with 20 ng/ml EGF and 10 ng/ml basic FGF. After 4 days, the cells in the upper wells were removed, whereas the cells that migrated to the lower wells were fixed, stained with DAPI in PBS 1% NP40 for 5 min and counted under a fluorescence microscope. The amount of migrated cells was quantified with the ImageJ program.
In vivo experiments. All animal experiments were conducted according to the national Animal Experimentation guidelines (D.L.116/92) upon approval by the ISS Animal Experimentation Committee. For tumorigenesis assays, female 6-8 weeks old NSG mice were subcutaneously injected with 10 3 dissociated spheroid cells resuspended in 100 μl Matrigel -CSC medium 1 : 1. Tumor volume was evaluated by using an external digital caliper. For in vivo inducible CR1 silencing, doxycycline 200 μg/ml was kept in the drinking water throughout the experiment. For experiments of CSC homing/metastasis, 10 4 dissociated spheroid cells were injected into the caudal vein and tumor formation was monitored with an IVIS imaging system (Perkin Elmer, Waltham, MA, USA). For serial transplantation experiments, cells derived from dissociated xenografts were kept in culture overnight in the presence or in the absence of doxycycline and inoculated subcutaneously. Doxycycline was provided to mice throughout the experiment. Quantification of stem cell numbers was performed with the ELDA method. 25 For heterotopic spleen injection NSG mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) injected into the peritoneal cavity. 2 × 10 4 CSC transduced with TRIPZ sh4890 and TWEEN-LUC-GFP were injected in the spleen during open laparotomy and mice were monitored with IVIS. After primary tumor formation the spleen was removed and doxycycline was added in the drinking water of the shCR1 group. Liver metastasis growth was monitored with IVIS once a week for six weeks.
Statistical analysis. Data were analyzed using the R software with non-paired double-tailed t test after verifying normal distribution of the population with ShapiroWilk test. Results are presented as the mean ± S.D. Statistical significance is expressed as *P-value 0.01-0.05; **P-value 0.001-0.01 and ***P-value o0.001.
